|
Saturday 26 October |
Tiago Lopes - Unit of Mechanisms of Disease
Title: “Into the structure of human full-length Smads and the impact of cancer mutations"
Date and Time: Tuesday, 5th November 2019, 15:00h.
Place: Fèlix Seratosa, Parc Científic de Barcelona
Organizers: IRB Barcelona
Date: Friday 8 November, 12.00h
Place: Felix Serratosa, Parc Cientific de Barcelona
Plenary Seminar
Date: 13-15 November 2019
Place: Van der Valk hotel, Nijmegen (Netherlands)
Early bird registration period: April 1 – June 30, 2019
Notification of travel grants awardees: July 31, 2019
Late registration period: July 1 – September 16, 2019
Notification of abstract selection: October 2019
Register here:
http://enablenetwork.eu/registration/
Stimulation of the immune system by blocking immunosuppressive checkpoints has shown spectacular impact in cancer therapy. There is increasing evidence that immunotherapy might elicit similar outcomes in non-oncological settings. This is the case, for example, of neurodegenerative disorders where blockade of immune checkpoints has beneficial effects. More generally, aging is associated with a progressive unbalance in the composition and activity of the different components of the immune system.
Organizers: IRB Barcelona
Date: Friday, 22nd November, 12.00h
Place: Fèlix Serratosa, Parc Cientific de Barcelona
Host: Marco Milán, PhD. and Jens Lüders, PhD, Group Leaders, IRB Barcelona, Mechanisms of Disease Programme.
Abstract:
Organizers: IRB Barcelona
Date: Wednesday, 27th November, 12.00h
Place: Fèlix Serratosa, Parc Cientific de Barcelona
Host: Patrick Aloy, PhD., Group Leader, IRB Barcelona, Mechanisms of Disease Programme.
Abstract:
Ricardo Viais - Unit of Mechanisms of Disease
Title: "The role of microtubule nucleation during neural development"
Date and Time: Friday, 13th November 2019, 10:00h.
Place: Fèlix Seratosa, Parc Científic de Barcelona
Cancer is the second leading cause of death worldwide, and a problem that escalates in an aging population. Although significant progress has been made in understanding the genetic and epigenetic determinants of cancer, little attention has been paid to post-transcriptional regulation of gene expression. The process of mRNA translation shapes the proteome and plays an essential role in the reprogramming of cancerous cells, holding the promise of novel anti-cancerous therapies.